February 6, 2021, 9:56 pm EST
Fighting COVID-19: Gilead Sciences Inc (GILD)
There is nothing more important than fighting COVID-19 for 2021 when global death reaches 2.3 million and US death is getting closer to a half million. Demand for vaccines is from the entire population of this earth and there is always a shortage to produce enough vaccines for the near future. Furthermore, more variations of this deadly disease keep increasing so it is likely this battle will last for a long period of time. Thus, biotech or bio-pharmaceutical companies could make a big impact if their vaccines are effective and available.
Gilead Sciences Inc (GILD) jus release its 2020 Q4 earning report on 02/04 that shows GILD could be one of the winners in this vaccine race:
- Q4 sales increased 26% YoY primarily due to $1.9B of Veklury sales
- Dividend 4.15%
- Strong technical setup with two gap-ups and ready to potential uptrend
- Entry point 69 and sell-stop 64
